29 patents currently held
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2030. from the record
Of the 9 now held by other companies, 9 name Tonix Medicines Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Sep 2030
Next term end
13
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2034 · High confidence
Also notable
Ends Jun 2031 · High confidence
Also notable
Ends Sep 2030 · High confidence
Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
US 10,117,936
The most cited patent in this portfolio, cited by 40 later US patents, top 10% of utility patents granted in 2018 in our data. Protection runs to 2034.
Methods and Compositions for Treating Fatigue Associated with Disordered Sleep Using Very Low Dose Cyclobenzaprine
US 9,474,728
Cited by 29 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Method for treating neurocognitive dysfunction
US 9,314,469
Cited by 23 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Formerly held, still cited
Notable
Ends Jun 2030 · Low confidence
Cited by 13 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Tonix Medicines, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Eutectic Formulations of Cyclobenzaprine Hydrochloride (US 10,357,465) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride (US 11,737,991) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Apr 22, 2027The maintenance fee for Tianeptine Oxalate Salts and Polymorphs (US 10,449,203) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Cyclobenzaprine Treatment for Agitation, Psychosis and Cognitive Decline in Dementia and Neurodegenerative Conditions (US 11,826,321) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride (US 11,839,594) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
- 1 fee due Jul 19, 2027The maintenance fee for Methods for Treatment of Pain (US 9,238,053) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
- 2 fees due Oct 19 to 30, 2027 · next Oct 19
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride | 11 in force | to Sep 2035 |
| Labeled Oxytocin and Method of Manufacture and Use | 2 in force | to Apr 2039 |
| Synthetic Chimeric Poxviruses | 2 in force | to May 2038 |
| Tianeptine Oxalate Salts and Polymorphs | 2 in force | to Dec 2037 |
| Magnesium-Containing Oxytocin Formulations and Methods of Use | 2 in force | to Jan 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,314,469 | Method for treating neurocognitive dysfunction In force · High confidence | In force | High confidence | |
| US 9,238,053 | Methods for Treatment of Pain In force · High confidence | In force | High confidence | |
| US 9,918,948 | Methods and Compositions for Treating Symptoms Associated with Post-Traumatic Stress Disorder using Cyclobenzaprine In force · High confidence | In force | High confidence | |
| US 9,474,728 | Methods and Compositions for Treating Fatigue Associated with Disordered Sleep Using Very Low Dose Cyclobenzaprine In force · High confidence | In force | High confidence | |
| US 10,722,478 | Methods and Compositions for Treating Fatigue Associated with Disordered Sleep Using Very Low Dose Cyclobenzaprine In force · High confidence | In force | High confidence | |
| US 8,551,949 | Methods for Treatment of Pain In force · High confidence | In force | High confidence | |
| US 11,998,516 | Methods and Compositions for Treating Depression using Cyclobenzaprine In force · High confidence | In force | High confidence | |
| US 9,636,408 | Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride In force · High confidence | In force | High confidence | |
| US 9,956,188 | Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride In force · High confidence | In force | High confidence | |
| US 10,117,936 | Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride In force · High confidence | In force | High confidence |
Also on record, not counted in the 29: 9 patents in force now held by others · 20 applications pending · 15 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.